Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3.8 m GLTA
I know this article is from 2022 , but it reminds you that they have been working on this approx 7 to 8 months now. I am thinking it is about that time they release news where they are at. Either completed and now are in production or something along that line. Have a great weekend all. GLTA
https://www.nasdaq.com/press-release/enzolytics-inc.-announces-collaboration-with-abveris-to-discover-monoclonal
Little more DD is needed , the case with Savov is for the 71.9 million shares Enzolytics is sueing to get that are currently being held. They will not be using part of the 900m to settle with him. Maybe they split the 71.9m share to resolve but not giving him more than 71.9m at the most.
All they did was increase A/S not issue at this point. GLTA
Good luck next week Cat.
Space Recording Here??
https://twitter.com/i/spaces/1mnGeROEPXqJX
$ENZC 🎙 Space Recorded 🎙
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) May 4, 2023
I will share my sources of the discussion in this thread. Thank you all for joining, none of this would matter without @drgauravchandra and the Enzolytics teams' strategic achievements!
Space Recording Here👇https://t.co/z0tNfdomf5 https://t.co/DmrpeO3VKF
Thank you , Hopefully we start seeing PRs and news over the upcoming weeks. After more than 2 years what is a few more weeks or even months. GLTA
Can you post that link . Thank you
Hopefully it is here is a link , they have til 5/17 is last update
https://www.pacermonitor.com/public/case/44729395/Savov_v_Empire_Stock_Transfer,_Inc
Been here since before the first run Jim , will be here for the one that takes us over
$ 5.00 . GLTA
Well hopefully with the highs of the last two day we shouldn't have thoses shares being sold in the 7s & 8s.. Which should help hold the share price. GLTA
Seems like a few oldies are coming out Jim , now all we need to see is Law show up. Last I heard from him he was on the fence about ENZC hopefully he has made his mind up. Are you reviewing the applications for new staff. GLTA
Maybe the 900 million was to pay the dividend at a rate of .30 per share and issue it as of holders of Enzolytic stock Jan. 30 20223. Meaning if you had a million shares you would get 300k shares of ENZC not cash. The 250 million goes into assets holding for the futures testing
Just a thought GLTA .
Our volume must be helped from the SAGA buyers , ETrade has a volume of 5 showing for them today GLTA
Better to be trading in .05 than the .04's , you haven't been predicting to much lately what's up? GLTA
I was thinking along that line, yet we are hearing this BP this BP so they are tied in someway if true. I think animal trials are further along with Abveris than we think and let's not forget about Mountana that we never got results or any type of news from. If they deliver on just 1/3 of what was talked about in 2020-2021 era everyone will be happy. Remember ENZC stood for Entering New Zip Code back in the day .
Good hearing from you now I hope you have been working on updating your picture catalogue to start showing us.
GLTA
Just asking to see what type of speculation will be given, and I am long just trying to make sense of it all.
If we have dealings with BP why wouldn't one of them do a deal like Saga with Enzolytics. They have the money and would have exclusive rights ect what is the difference? A structure deal is a structure deal that can be drawn up in the same benifit package ect that may or may not be written in the SAGA deal.
GLTA
In the filing, keep in mind their 3 year contracts are up in Oct 2023.
Thanks I saw this , just nothing on their website. Hard to tell what actually is happening til we see it. With that and the timeframe of 17 weeks stated as the test time, I would say this deal won't go thru for another 4.5 months. GLTA
I don't see it on their website , sorry
Enzolytics, Inc. (the “Company” or “ENZC”), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ: SAGA) (“Sagaliam”), a special purpose acquisition company (“SPAC”), announced today, April 17, 2023, they have executed a non-binding term sheet for the sale of Biogenysis, Inc. (“BGEN”) and Virogentics, Inc. (“VIRO”), operating subsidiaries of Enzolytics. The value of the transaction is $250,000,000.00. The definitive agreement is being finalized with an expected closing date of May 19, 2023
We will see how it plays out. I hope your right . GLTA
No problem , this has a while until we know what really is happening. This company has been put on notice by NASDAQ, has extend deals and have not followed thru on others. A non bidding is not a good sign for a deal that is to happen in less than a month. Just don't want people to get their hopes up. Sorry if you think it is a downer tone, DD goes along way. Been long for years and I do hope it works out just looking at their history. GLTA
This has nothing to do with ENZC , this is a deal they have been working on since 2021. That they keep extending . Here is the filing https://quantisnow.com/insight/4370195
Time will tell , but this won't hold dollars for something that is not going anywhere. Koos still has no news for shareholders, yet his last EGC said they had new news on test resulting should be a couple of days. 6 weeks out , no uplist no news. Only thing happening is trying to sell BS shares for 2.00. The sale to raise 2 million doesnt pay debt and won't fund ongoing scam for long. Most have posted they need 25 30 50 dollars just to break even. Wont be happening, if they sold and took the tax lost the share price would be in the pennies. They are staying hoping to get a pop to get out , that pop won't be that big nor will it last if it even does go up. Once reality sets in they will dump and the price will follow. GLTA
Fdc4
Re: bigtalan post# 117237
Saturday, February 18, 2023 5:25:28 PM
Post#
117240
of 117930
You are misunderstanding, the R/S It is good intentioned and it WAS a good idea but it has been PROVEN that it is not going to end up well if Koos continues this path. The PPS speak for itself and WE wont last 48 hrs over a dollar in here. I am buying because I want to stay over 1M shares if he continues with the R/S idea, nothing else. I am not a weak hand, never sell mate, this is the way I do.
How are you doing now mate ?
As of March 31, 2023 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $710. $710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. Very interesting you have 87k on hand but you have to be lent 710 by the CEO at 15%, makes sense to me
On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. Rent to another company you own makes sense to me
BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.
As of March 31, 2023 we had $87,700 in cash on hand and current liabilities of $5,336,389. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing. You just stoled 4.977Billion shares and you still owe people money gotta love it .
As of March 31, 2023 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.
IMO GLTA
Just thinking outside the box, but a few years back the primate testing was taking place in Minnesota I think. I have reached out many times and have not got responses, if I did it was no comment. I posted them here awhile back. With the entry into Africa is it possible that the primate (aka ENZO ) has been cured and that is why Africa is proceeding with trials on humans aslong as the toxicity was safe, which required the third 28 day test to prove. Kinda wierd to go to human first without the animals not to be involved first usually the animal is tested and then followed by human based of exceptable levels and results. I think that theirs much testing that has taking place over the last 2 years. The results along with Toxicity ranges most likely was the factor on green lighting the path into the various hospitals. Maybe it is a big head fake to bring in new investors by a few select BP to have a bidding war over running different division using Enzolytics patents and management teams. Just another hot mess of one pathway, which appears there are many to follow for now until we get news or PRs ..I feel 1000% we are on the right track moving forward.. AIMO GLTA
Why would you give this up when you just filed everything unless you are planning on holding all pantents and then license them out thru the two sold off companies. This should be a very interesting few weeks upcoming to see if any details or other news is released. With the statements below I would say alot of money to be made off of the cats alone, not counting all the other animals they have been working on. A partnership with Zoetis I would think would have been a better way and a pure revenue source for years. Time will tell what is actually happening.
Enzolytics Announces Progress in The Development and Patenting of Feline Leukemia Monoclonal Antibodies.
COLLEGE STATION, TX / ACCESSWIRE / April 4, 2023/ Enzolytics, Inc. (OTC PINK: ENZC) (https://enzolytics.com/).
Enzolytics today announced progress on its ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using the Company’s Artificial Intelligence technology, more than 26 immutable epitope sites on the FeLV virus have been identified. These sites are claimed in the filed patent application. The patent covers the use of any of its discovered numerous conserved Feline Leukemia epitopes in the production of monoclonal antibodies, the production of vaccines, or use in diagnostic tests for detecting the virus in cats. The Company’s wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.
While the Company's focus is on producing monoclonal antibodies for treating numerous human viruses, including COVID-19, HIV, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA), the Company has also analyzed epitopes of animal viruses, namely the Cat Feline Leukemia Virus (FeLV), Horse Equine Infectious Anemia Virus, Chicken Anemia Virus, Koala Retrovirus (KoRV), Elephant Endotheliotropic Herpes Virus (EEHV), Avian Flu Swine Flu, This analysis has revealed the conserved immutable sites on these viruses against which monoclonal antibody production is planned. The findings will ultimately be claimed in U.S. and foreign patent applications.
Targeting the conserved sites discovered by Enzolytics allows the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. Even a “variant form of the virus” will contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Currently, there is no cure for Cat Feline Leukemia (FeLV) virus. The cost of treatment of the virus is significant. There are more than 45 million cats in the U.S. and over 25% of households in America own one or more cats. FeLV is one of the most common infectious diseases in cats. This virus affects a significant percentage of the cat population in the United States, resulting in millions of cats suffering from it. This same problem exists around the world in the world population of 600 million cats.
Production of monoclonal antibodies targeting this animal virus and bringing this therapy to market will be more direct and the time to treatment of animals will be significantly less than is the case required for monoclonal antibodies developed for the treatment of individuals. The Company has initiated discussions with animal health providers who express an interest in this technology and its end product.
The production of these monoclonal antibodies begins in the Company’s lab located at the Texas A&M University Institute for Preclinical Studies [https://tips.tamu.edu/]. The lab uses the Company's proprietary methodology for producing fully species-specific monoclonal antibodies which target conserved, immutable sites on the viruses, thereby avoiding ineffectiveness due to virus mutation.
The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of the Company’s pending international patent applications. In the initial process step, Artificial Intelligence (AI - computer analysis) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary AI platform. In the AI initial analysis process step, the sequences (structure) of virus isolates are analyzed. From that analysis, epitopes (target sites) are identified which are conserved across all isolates curated. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.
As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets may be analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Then Enzolytics produces multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.
Enzolytics' methodology for producing monoclonal antibodies is unique and innovative, unlike those employed by other biotech companies. In the case of a monoclonal antibody to treat an animal virus, the Company's antibodies are produced from animal "immune-B cells", obtained from convalescent animals who have recovered from the target virus. The Company's monoclonal antibodies are then developed directly where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.
Yes I figured you were using pre startup ( rebranding ) just not a good look when you look at finincals, revenue and the cash on hand and what they started with from IPO. IMO GLTA
Interesting reads about non binding term sheet and what they could or could not include. Either this has been in the works for awhile and kept under wraps very well or like others have stated it could take much longer than this month to iron out. I know that we have one of the best Patent lawyers working on it , so again just looking at everything involved and what it actually curtails. Hopefully this has been in the works, because it does involve alot of moving parts currently to wrap up in a month time. And still nothing on Enzolytics home page alittle weird GLTA
https://corporatefinanceinstitute.com/resources/valuation/term-sheet-guide/
https://www.mintz.com/insights-center/viewpoints/2013-07-08-when-non-binding-term-sheet-becomes-binding
https://thestartuplawblog.com/term-sheets-binding-non-binding/
https://www.lsu.edu/innovation/faculty/files/nonbindingtermsheet.pdf
https://www.lawinsider.com/clause/non-binding-term-sheet
I am hoping that we are just around the corner of the news we all have been waiting from Africa and will be positive and in short order( 2 months ) . I did read the Newsy article also much of the same no real concrete facts that the other didn't have and speculation about what Enzolytics is getting from it. That all won't be known until they release the structure of the deal in May. Either way it should be a fun month ahead to see what gets released, what gets reported ,and what names get dropped.
I am hoping this deal makes it on time and we are not caught up like the last few handled by SAGA extentions we have had enough of thoses over the past 2.5 years. Late May could bring a .25 SP if the right news and or results start coming out. All just a guessing and connecting the dots at this point, and todays dot board was out of left field and proves they can keep information silent until it is released. No boards had a clue of this 250 milliom sale until they read the news release. We all have three options Buy Hold Sell so noone now should have the sky is falling, ect.. the time is now to buy in hold or add or shut up sell and find another company to invest in if you don't see what Africa will be brining in real soon, and EAU soon after. I am just holding and waiting . GLTA
I ran out of post yesterday so sorry for the late reply had to get reloaded with 15 at midnight EST .
Which SAGA are you looking at , formed two years ago
https://www.wsj.com/market-data/quotes/SAGA/company-people
Description Sagaliam Acquisition Corp. Cl A
Sagaliam Acquisition Corp. is a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more entities. The company was founded on March 31, 2021 and is headquartered in Los Angeles, CA.
Yes totally agree Saga could just be a "sponsor" when it is really looked at when and if the deal goes thru. We wont know that for about a month now .
GLTA
https://finance.yahoo.com/quote/SAGA/profile?p=SAGA
Thanks Jack , that was a question I was asking about who would hold the patents , and who was a licensee of said products. One comment came back as the patents would go with companies. I did not think they would since everything has been filed under Enzolytics recently. EX AI , animal ect.. If that is the case then if they can raise the money it is a win win because Enzolytics would be getting a royalty of some sort I would image on the products . GLTA
Yes i know they have three ticker , I used the SAGA .
Sagaliam Acquisition Corp has completed one deal in 2022. On November 16, 2022 Sagaliam entered into a Business Combination Agreement (the “BCA”) with Allenby Montefiore Limited, a private company limited by shares organized and existing under the Laws of the Republic of Cyprus, AEC Merger Sub Corp., a Delaware corporation, Supraeon Investments Limited, a private company limited by shares organized and existing under the Laws of the Republic of Cyprus and GLD Partners, LP, a Delaware limited partnership 1.
Really coming from you .
Thanks Capt and Docsetc, I know it wasn't what people wanted to hear but facts are facts. 250 million for what Enzolytics has been saying is a 110 Billion over 10 years is crazy. Like I posted earlier that basically is .08 to shareholders I don't see management giving most of it away for .08 and 2.5 years of work. Maybe I am wrong but I think they know it is worth more than that. IMO